AstraZeneca, flag

AstraZeneca topped off a very busy week with the company’s first-quarter 2022 financial report, citing a total of $11.39 billion in revenue, a whopping increase of 60 percent. That performance was driven by the acquisition of Alexion and several contracts for Vaxzevria, AstraZeneca’s COVID-19 vaccine developed with the University of Oxford.

Peregrine Market Access, a leading consultant agency for the life sciences industry, earned its place as number 589 on the Inc. 5000 list of the nation’s fastest-growing private companies. The list represents a unique look at the most successful companies within a dynamic segment of the American economy—its independent small businesses.

CrowdPharm

CrowdPharm, an independent full-service agency fueled by one of the largest healthcare talent networks in the world, was recognized on Inc. Magazine’s annual list of the 5,000 fastest-growing companies in America.

Cross & Wild, an independent full-service advertising agency and strategic consultancy, was recognized on Inc. Magazine’s annual list of the 5,000 fastest-growing companies in America.

Pfizer reported first-quarter 2021 revenue of $14.6 billion, an impressive 42 percent operational growth. The company’s Covid-19 vaccine revenue accounted for $3.5 billion of the total.

AstraZeneca

AstraZeneca entered into a definitive agreement to acquire Alexion Pharmaceuticals for a total consideration to Alexion shareholders of $39 billion or $175 per share.

To support the long-term goals of Novartis, the Swiss pharma giant is initiating a share-buyback program of up to $2.5 billion that is expected to be carried out over the next few months.

With a busy week for biotech quarterly and annual reports, here is a look at some of the top stories.